Analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a report released on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.
OpGen Trading Down 4.2 %
Shares of OPGN stock opened at $0.68 on Friday. OpGen has a 1 year low of $0.17 and a 1 year high of $3.84. The firm’s fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.50. The firm has a market capitalization of $6.81 million, a P/E ratio of -0.10 and a beta of -0.71.
Institutional Investors Weigh In On OpGen
Several institutional investors and hedge funds have recently made changes to their positions in OPGN. Citadel Advisors LLC boosted its stake in shares of OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85,754 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of OpGen by 39.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after purchasing an additional 534,960 shares in the last quarter. HRT Financial LP acquired a new stake in shares of OpGen in the 4th quarter valued at $26,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of OpGen in the 1st quarter valued at $49,000. Institutional investors and hedge funds own 2.68% of the company’s stock.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Stories
- Five stocks we like better than OpGen
- NYSE Stocks Give Investors a Variety of Quality Options
- 5 Trends You Need to Know This Quarter
- How to Invest in Biotech Stocks
- MarketBeat Week in Review – 4/8 – 4/12
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
